Haining Health-Coming Biotech Co., Ltd.   Report issue

For profit Phase 2
Founded: Beijing China (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2018
NCT03407300
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Haining Health-Coming Biotech Co., Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

docetaxel (taxotere) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 2)

Lung Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1